Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.34 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.34 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6317673 | 1.00 | MMP13 (0.39) | MMP13ITGB3ITGA2BRENADORA1 | |
| SCHEMBL1325198 | 1.00 | MMP13 (0.39) | MMP13ITGB3ITGA2BRENADORA1 | |
| SCHEMBL4778626 | 0.88 | CTSS (0.44) | MMP13ITGB3ITGA2BRENADORA1 | |
| SCHEMBL25336642 | 0.88 | LDHA (0.36) | ITGB3ITGA2BLDHASLC7A5ITGA4 | |
| SCHEMBL8766144 | 0.88 | CTSS (0.44) | MMP13ITGB3ITGA2BRENADORA1 | |
| SCHEMBL25336645 | 0.88 | LDHA (0.36) | ITGB3ITGA2BLDHASLC7A5ITGA4 | |
| SCHEMBL25173080 | 0.88 | PPARG (0.40) | MMP13ITGB3ITGA2BRENADORA1 | |
| SCHEMBL6661008 | 0.88 | CTSS (0.44) | MMP13ITGB3ITGA2BRENADORA1 | |
| SCHEMBL1401042 | 0.87 | MMP13 (0.46) | MMP13ITGB3ITGA2BRENSLC7A5 | |
| SCHEMBL2476924 | 0.87 | MMP13 (0.46) | MMP13ITGB3ITGA2BRENSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492345-B2 | Cyclic peptide antitumor agents | NORTHWESTERN UNIVERSITY (US) | 2013-07-23 | — | — | US | disclosed |
| US-20120122799-A1 | CYCLIC PEPTIDE ANTITUMOR AGENTS | NORTHWESTERN UNIVERSITY (US) | 2012-05-17 | — | — | US | disclosed |
| US-8058244-B2 | Cyclic peptide antitumor agents | NORTHWESTERN UNIVERSITY (US) | 2011-11-15 | — | — | US | disclosed |
| US-20100204088-A1 | Cyclic Peptide Antitumor Agents | SILVERMAN RICHARD B | 2010-08-12 | — | — | US | disclosed |
| US-7709443-B2 | For treatment of human melanoma, pancreatic, breast, prostate cancer cells | NORTHWESTERN UNIVERSITY (US) | 2010-05-04 | — | — | US | disclosed |
| EP-1017382-B1 | BIARYLALKANOIC ACIDS AS CELL ADHESION INHIBITORS | MERCK & CO INC (US) | 2006-03-01 | — | — | EP | disclosed |
| US-6939880-B2 | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 2005-09-06 | — | — | US | disclosed |
| US-20050159346-A1 | Cyclic peptide antitumor agents | NORTHWESTERN UNIVERSITY | 2005-07-21 | — | — | US | disclosed |
| US-6900213-B2 | Bisaryl derivatives having FSH modulatory activity | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| WO-2005034982-A1 | CYCLIC PEPTIDE ANTITUMOR AGENTS | NORTHWESTERN UNIVERSITY (US) | 2005-04-21 | — | — | WO | disclosed |
| US-6127391-A | A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY | NOVO NORDISK A/S (DK) | 2000-10-03 | — | — | US | disclosed |
| EP-1017382-A4 | BIARYLALKANOIC ACIDS AS CELL ADHESION INHIBITORS | MERCK & CO INC (US) | 2000-08-30 | — | — | EP | disclosed |
| EP-1017382-A1 | BIARYLALKANOIC ACIDS AS CELL ADHESION INHIBITORS | Merck & Co., Inc. (a New Jersey corp.) (US) | 2000-07-12 | — | — | EP | disclosed |
| US-5977178-A | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 1999-11-02 | — | — | US | disclosed |
| WO-1998053817-A1 | BIARYLALKANOIC ACIDS AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1998-12-03 | — | — | WO | disclosed |
| EP-0869974-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997023508-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1997-07-03 | — | — | WO | disclosed |
| EP-0677043-A4 | — | — | 1995-11-22 | — | — | EP | disclosed |
| EP-0677043-A1 | PLATELET AGGREGATION INHIBITING COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-10-18 | — | — | EP | disclosed |
| WO-1994014775-A1 | PLATELET AGGREGATION INHIBITING COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204088-A1 | Cyclic Peptide Antitumor Agents | VIP, IAPP, NGLY1 | MMP13 603/4885ITGB3 3849/4885ITGA2B 4246/4885 |
| US-20120122799-A1 | CYCLIC PEPTIDE ANTITUMOR AGENTS | VIP, IAPP, NGLY1 | MMP13 603/4885ITGB3 3849/4885ITGA2B 4246/4885 |
| US-20050159346-A1 | Cyclic peptide antitumor agents | VIP, IAPP, NGLY1 | MMP13 603/4885ITGB3 3849/4885ITGA2B 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.